FDA Clears Rapid COVID Test Offering Triple the Accuracy
Washington, Friday, 18 September 2026.
Aptitude Medical Systems secured official FDA clearance for its upgraded COVID-19 test, delivering three times greater sensitivity and 30% faster results for both home and clinical use.
FDA Clearance Secured for Next-Generation Diagnostic
Aptitude Medical Systems has successfully obtained 510(k) clearance from the U.S. Food and Drug Administration for its next-generation Metrix COVID-19 molecular diagnostic test [1][2]. This regulatory milestone was achieved on 15 September 2026, marking the company’s first traditional clearance for the platform as it transitions away from Emergency Use Authorization [1][3]. The clearance arrives amidst a reported autumn uptick in viral transmission, positioning the device for renewed commercial relevance in point-of-care settings [1]. Health officials note that such approvals are critical as the healthcare sector prepares for the scheduled termination of COVID-19 EUA declarations for medical devices later this year [2][3].
Enhanced Sensitivity and Operational Speed
The newly cleared assay delivers approximately 3-fold greater analytical sensitivity compared to the original EUA-authorized product, significantly improving detection capabilities [1][2]. In addition to sensitivity improvements, the device generates results 30% faster than previous iterations, facilitating quicker clinical decision-making in decentralized environments [2][3]. The system is cleared for both over-the-counter and professional use in CLIA-waived settings, addressing historical barriers such as high costs and workflow complexity [1][2]. Hundreds of clinics, particularly urgent care centers, adopted the Metrix platform over the 12 months preceding the clearance, validating the demand for accessible molecular diagnostics [2][3].
Regulatory Transition and Timeline
The U.S. Department of Health and Human Services has scheduled the termination of COVID-19 EUA declarations for medical devices for 26 December 2026, creating a defined window for market transition [1][3]. From the current date of 18 September 2026, there are 99 days remaining until the regulatory deadline expires [2][3]. Previously distributed Metrix EUA-authorized products remain valid for use through their labeled expiration dates, ensuring continuity for customers during the transition period [1]. This timeline underscores the strategic importance of the 510(k) clearance, which allows continued commercialization beyond the EUA sunset date [2].
Expansion of Molecular Portfolio
Aptitude is actively expanding the Metrix molecular diagnostics platform to include tests for respiratory syncytial virus, Streptococcus, and sexually transmitted infections [1][2]. These additional assays are currently in late-stage development or under FDA review, reflecting the company’s strategy to broaden its menu beyond single-target respiratory testing [2][3]. Development of the platform was partially funded by the Biomedical Advanced Research and Development Authority, supporting the goal to expand where and how molecular testing is used [1][3]. Company leadership emphasizes that this clearance is an important step rather than a stopping point for the Metrix platform [1][2].